Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10293195" target="_blank" >RIV/00216208:11110/14:10293195 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023884:_____/14:#0007180

Výsledek na webu

<a href="http://dx.doi.org/10.1053/j.seminoncol.2014.09.009" target="_blank" >http://dx.doi.org/10.1053/j.seminoncol.2014.09.009</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1053/j.seminoncol.2014.09.009" target="_blank" >10.1053/j.seminoncol.2014.09.009</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields

Popis výsledku v původním jazyce

Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effectivestandard treatment for recurrent GBM. NovoTTF Therapy is a novel and US Food and Drug Administration (FDA)-approved antimitotic treatment for recurrent GBM with potential benefits compared with other options. Recurrent GBM patients from two prior trialswith demonstrated radiologic tumor response to single-agent NovoTTF Therapy were analyzed to better characterize tumor response patterns and evaluate the associations between response, compliance, and OS. In addition, a compartmental tumor growth modelwas developed and evaluated for its ability to predict GBM response to tumor-treating fields (TTFields). The overall response rate across both trials was 15% (4% complete responses): 14% in the phase III trial (14/120) and 20% (2/10) in a

Název v anglickém jazyce

Response Patterns of Recurrent Glioblastomas Treated With Tumor-Treating Fields

Popis výsledku anglicky

Glioblastoma multiforme (GBM) is the most common form of primary malignant brain cancer. Median overall survival (OS) for newly diagnosed patients is only about 12 to 18 months. GBM tumors invariably recur, and there is no widely recognized and effectivestandard treatment for recurrent GBM. NovoTTF Therapy is a novel and US Food and Drug Administration (FDA)-approved antimitotic treatment for recurrent GBM with potential benefits compared with other options. Recurrent GBM patients from two prior trialswith demonstrated radiologic tumor response to single-agent NovoTTF Therapy were analyzed to better characterize tumor response patterns and evaluate the associations between response, compliance, and OS. In addition, a compartmental tumor growth modelwas developed and evaluated for its ability to predict GBM response to tumor-treating fields (TTFields). The overall response rate across both trials was 15% (4% complete responses): 14% in the phase III trial (14/120) and 20% (2/10) in a

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

N - Vyzkumna aktivita podporovana z neverejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Seminars in Oncology

ISSN

0093-7754

e-ISSN

—

Svazek periodika

41

Číslo periodika v rámci svazku

October

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

11

Strana od-do

"S14"-"S24"

Kód UT WoS článku

000344310000003

EID výsledku v databázi Scopus

—